A Long-term Study for the Treatment of Painful Diabetic Neuropathy
Launched by ELI LILLY AND COMPANY · Mar 21, 2008
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Outpatients who have completed the 13-week treatment in the preceding study (Protocol No. 0715N0831: NCT00552175).
- • Patients who desire to receive continued treatment with LY248686 from the preceding study.
- • Patients with latest glycosylated hemoglobin (HbA1c) ≤9.0% before Visit 7.
- • Patients who can provide written consent in person.
- Exclusion Criteria:
- • Patients who concurrently have serious cardiovascular, hepatic, renal, respiratory, or blood disease, or symptomatic peripheral vascular disease, and thus are considered inappropriate to be included in the study.
- • Pregnant patients or women who desire to become pregnant during the study period, and breast feeding patients.
- • Other patients judged by the investigator/subinvestigator to be inappropriate as a subject in this study.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aichi, , Japan
Chiba, , Japan
Fukuoka, , Japan
Hyogo, , Japan
Niigata, , Japan
Osaka, , Japan
Saitama, , Japan
Fukui, , Japan
Hokkaido, , Japan
Miyagi, , Japan
Tochigi, , Japan
Tokushima, , Japan
Toyama, , Japan
Fukushima, , Japan
Gunma, , Japan
Kagoshima, , Japan
Tokyo, , Japan
Aomori, , Japan
Hiroshima, , Japan
Kyoto, , Japan
Oita, , Japan
Kanagawa, , Japan
Okayama, , Japan
Ibaragi, , Japan
Sizuoka, , Japan
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials